Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Australian Prescriber
|
December 6, 2023
Chimeric antigen receptor T-cell therapy
Cale Burge, Vinay Vanguru, Phoebe Joy Ho
Leukemia & Lymphoma
|
February 22, 2021
Bioinformatic gene expression analysis demonstrates a limited number of multiple myeloma specific therapeutic targets
Murari Ramesh, James Favaloro, Christian Bryant, et al.
Frontiers in Immunology
|
March 12, 2021
Treg and Oligoclonal Expansion of Terminal Effector CD8<sup>+</sup> T Cell as Key Players in Multiple Myeloma
Douglas E Joshua, Slavica Vuckovic, James Favaloro, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
November 1, 2007
Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study
Richard H Osborne, Richard De Abreu Lourenço, Andrew Dalton, et al.
Leukemia & Lymphoma
|
November 4, 2009
Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma
Ross D Brown, Andrew Spencer, Phoebe Joy Ho, et al.
Expert Review of Hematology
|
October 13, 2025
Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia
Angelina Yong, Kate Vandyke, Bradley Augustson, et al.
Internal Medicine Journal
|
November 28, 2022
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Dipti Talaulikar, Douglas Joshua, Phoebe Joy Ho, et al.
Frontiers in Oncology
|
September 4, 2025
Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma-importance of pre-CAR-T optimization
Phoebe Joy Ho, Vinay Vanguru, Cale S Burge, et al.
European Journal of Haematology
|
June 15, 2021
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction
Stephen Boyle, Cameron Wellard, Elizabeth M Moore, et al.
Internal Medicine Journal
|
February 8, 2018
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma
Hang Quach, Simon Benson, Helen Haysom, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Australian Prescriber
|
December 6, 2023
Chimeric antigen receptor T-cell therapy
Cale Burge, Vinay Vanguru, Phoebe Joy Ho
Leukemia & Lymphoma
|
February 22, 2021
Bioinformatic gene expression analysis demonstrates a limited number of multiple myeloma specific therapeutic targets
Murari Ramesh, James Favaloro, Christian Bryant, et al.
Frontiers in Immunology
|
March 12, 2021
Treg and Oligoclonal Expansion of Terminal Effector CD8<sup>+</sup> T Cell as Key Players in Multiple Myeloma
Douglas E Joshua, Slavica Vuckovic, James Favaloro, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
November 1, 2007
Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study
Richard H Osborne, Richard De Abreu Lourenço, Andrew Dalton, et al.
Leukemia & Lymphoma
|
November 4, 2009
Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma
Ross D Brown, Andrew Spencer, Phoebe Joy Ho, et al.
Expert Review of Hematology
|
October 13, 2025
Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia
Angelina Yong, Kate Vandyke, Bradley Augustson, et al.
Internal Medicine Journal
|
November 28, 2022
Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Dipti Talaulikar, Douglas Joshua, Phoebe Joy Ho, et al.
Frontiers in Oncology
|
September 4, 2025
Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma-importance of pre-CAR-T optimization
Phoebe Joy Ho, Vinay Vanguru, Cale S Burge, et al.
European Journal of Haematology
|
June 15, 2021
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction
Stephen Boyle, Cameron Wellard, Elizabeth M Moore, et al.
Internal Medicine Journal
|
February 8, 2018
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma
Hang Quach, Simon Benson, Helen Haysom, et al.
Page
of 2